NASDAQ:BCEL Atreca (BCEL) Stock Price, News & Analysis → The CHIPS Act Motherlode (From True Market Insiders) (Ad) Free BCEL Stock Alerts $0.09 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.06▼$0.2152-Week Range$0.05▼$1.26Volume36,801 shsAverage Volume136,524 shsMarket Capitalization$3.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Atreca alerts: Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Atreca Stock (NASDAQ:BCEL)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Read More BCEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCEL Stock News HeadlinesApril 23, 2024 | ca.finance.yahoo.comAtreca, Inc. (BCEL) Stock Price, News, Quote & History - Yahoo FinanceApril 21, 2024 | nz.finance.yahoo.comAtreca, Inc. (0C1.MU)February 18, 2024 | wsj.comAtreca Inc. Cl AFebruary 15, 2024 | benzinga.comAtreca Stock (NASDAQ:BCEL), Short Interest ReportFebruary 7, 2024 | msn.comAtreca Inc Announces Executive Departures and Consulting AgreementsDecember 29, 2023 | bizjournals.comImmunome to buy assets from California biotech companyDecember 26, 2023 | tmcnet.comBCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.December 21, 2023 | thestreet.comAtreca Inc.December 11, 2023 | benzinga.comAtreca Stock (NASDAQ:BCEL) Dividends: History, Yield and DatesNovember 16, 2023 | morningstar.comAtreca Inc Class A BCELNovember 14, 2023 | marketwatch.comAtreca to Cut About 40% of WorkforceNovember 14, 2023 | finance.yahoo.comAtreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic AlternativesNovember 2, 2023 | es.investing.comAtreca Inc (BCEL)October 24, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Atreca IncOctober 12, 2023 | benzinga.comWhat's Going On With Atreca Inc Stock?October 12, 2023 | bizjournals.comMid-Peninsula building rode biotech's boom. Now it's showing how to survive the bustSeptember 21, 2023 | finance.yahoo.comAtreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb CrossAugust 11, 2023 | msn.comHC Wainwright & Co. Downgrades Atreca Inc - (BCEL)August 11, 2023 | msn.comStifel Downgrades Atreca Inc - (BCEL)August 11, 2023 | finance.yahoo.comAtreca Reports Second Quarter 2023 Financial Results and Announces Corporate RestructuringAugust 2, 2023 | msn.comAtreca Inc - (BCEL) Price Target Increased by 11.89% to 10.20June 20, 2023 | msn.comAtreca Approaches A Major Go/No-Go DecisionJune 6, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)June 5, 2023 | msn.comHC Wainwright & Co. Reiterates Atreca Inc - (BCEL) Buy RecommendationJune 5, 2023 | finance.yahoo.comAtreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual MeetingSee More Headlines Receive BCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCEL CUSIPN/A CIK1532346 Webwww.atreca.com Phone(650) 595-2595FaxN/AEmployees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.90% Return on Assets-71.39% Debt Debt-to-Equity RatioN/A Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book0.05Miscellaneous Outstanding Shares39,620,000Free Float35,146,000Market Cap$3.65 million OptionableOptionable Beta1.02 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. John A. Orwin M.B.A. (Age 59)President, CEO, Director & Principal Financial Officer Comp: $927.03kDr. Tito A. Serafini Ph.D. (Age 61)Founder & Director Comp: $665.5kMr. Rick Ruiz (Age 60)Principal Accounting Officer Ms. Courtney J. Phillips J.D. (Age 49)General Counsel & Corporate Secretary Roger Richard RuizVice President of FinanceKey CompetitorsGeoVax LabsNASDAQ:GOVXEvoke PharmaNASDAQ:EVOKZyVersa TherapeuticsNASDAQ:ZVSASeelos TherapeuticsNASDAQ:SEELPhaseBio PharmaceuticalsNASDAQ:PHASView All CompetitorsInsidersBros. Advisors Lp BakerSold 274,739 sharesTotal: $109,895.60 ($0.40/share)Tito SerafiniSold 5,487 sharesTotal: $5,212.65 ($0.95/share)Phillips CourtneySold 4,076 sharesTotal: $3,872.20 ($0.95/share)View All Insider Transactions BCEL Stock Analysis - Frequently Asked Questions Should I buy or sell Atreca stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares. View BCEL analyst ratings or view top-rated stocks. How have BCEL shares performed in 2024? Atreca's stock was trading at $0.1320 on January 1st, 2024. Since then, BCEL shares have decreased by 30.3% and is now trading at $0.0920. View the best growth stocks for 2024 here. How were Atreca's earnings last quarter? Atreca, Inc. (NASDAQ:BCEL) announced its earnings results on Tuesday, November, 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.74). What is John Orwin's approval rating as Atreca's CEO? 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend. What other stocks do shareholders of Atreca own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL). When did Atreca IPO? Atreca (BCEL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers. How do I buy shares of Atreca? Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCEL) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atreca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.